Overview
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Eligibility
Inclusion Criteria:
- Upper and/or lower extremity CRPS
- On stable treatment for 1 month
- CRPS for at least 1 year
- Meet the Budapest criteria for CRPS at time of the study.
Exclusion Criteria:
- Any known allergy to naltrexone or naloxone
- Use of prescription opioid analgesics or illegal opioid use
- Current or planned pregnancy.